Recent analysis by ChemAnalyst shows that the prices of Levetiracetam in the US fell further in April 2025 and maintained the bearish trend seen since March. The market continued to bear pressure from a mix of falling import costs, constantly high oversupply, and hesitant consumption. These conditions reinforced a weak pricing environment for Levetiracetam, with sentiment clouded by concerns around trade policy shifts, supply chain stability, and slowing export momentum.

• Prices for levetiracetam in the U. S. continued to collapse in April 2025 because of lower import prices and high levels of inventory.
• Chinese suppliers’ reduction of export prices made it more affordable for Levetiracetam imports.
• The levetiracetam market activity declined as the buyers bought ahead of the month early with expectations of tariff increases.
• Deflationary pressure on levetiracetam price was solidified by falling freight rates, weak global trade flows, and the conservative buying mentality among pharmaceutical firms.
• Levetiracetam price pressures are likely to remain downward biased in May 2025 with enforced oversupply and lifeless domestic and export needs.

In April, a sharp fall in export prices from China, the major global supplier, had a notable impact on Levetiracetam prices based on insights from market experts. Chinese Levetiracetam producers, who were facing a long-standing surplus and declining prices for inputs, kept on offering bulk volumes at lower prices. This facilitated U.S. importers in obtaining shipments at more competitive landed costs, encouraging domestic distributors to modify their pricing strategies to lower. Aware of possible tariff moves, various buyers accelerated their purchasing into the early part of the month, generating short term inventory buildup and subdued spot demand. At the same time, container activity from China reduced as a result of decreased global demand and mass order cancellations, sending a general message of reduced international trade activity.

Dropping freight rates further fueled cost reduction, boosting the price margin of Levetiracetam in favor of U.S. buyers. Yet, although there was a slight upgrade in the U.S. manufacturing indexes during the period, aggregate business sentiment declined. Market players mentioned persistent issues with volatility in input costs, availability of materials, and decreased export competitiveness, particularly considering changes in trade policies and macroeconomic uncertainty globally.

On the demand side of Levetiracetam, the pharmaceutical and healthcare sectors continued to maintain baseline consumption, but overall transactional volumes remained subdued. Most buyers adopted a cautious procurement strategy, prioritizing stock optimization over new orders. Export activity weakened for US as tariffs and soft overseas demand reduced U.S. competitiveness in foreign markets. The combined effect of these demand-side and supply-side dynamics led to a sustained decline in Levetiracetam prices over the month.

According to market experts, Levetiracetam prices in the U.S. are expected to decline further in May 2025, as excess supply and subdued demand continue to weigh on the market.